Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Will Focus On Six Therapeutic Areas

This article was originally published in The Pink Sheet Daily

Executive Summary

Merger will allow the partners to increase R&D in cardiovascular, antibacterial, glucose metabolic, bone disorder, immune disorder and anti-allergy categories. As a single entity, Daiichi and Sankyo expect to increase their combined 2,200-person global sales force.

You may also be interested in...



Forest, Daiichi Partner To Promote Hypertension Combo Azor Upon Approval

Forest Laboratories and Daiichi Sankyo are building upon an ongoing collaboration for Benicar and Benicar HCT with the signing of a new deal to co-promote the fixed-dose antihypertensive Azor, whose approval is anticipated in September. The companies announced the signing of a letter of intent to enter into a collaboration Aug. 21

Forest, Daiichi Partner To Promote Hypertension Combo Azor Upon Approval

Forest will pay Daiichi $20 million up front and provide a minimum number of product details in return for annual co-promotion payment.

Forest, Daiichi Partner To Promote Hypertension Combo Azor Upon Approval

Forest will pay Daiichi $20 million up front and provide a minimum number of product details in return for annual co-promotion payment.

Related Content

Topics

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel